Media stories about Cellular Biomedicine Group (NASDAQ:CBMG) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellular Biomedicine Group earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.9069538419175 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several equities research analysts have weighed in on CBMG shares. Zacks Investment Research raised Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a research report on Wednesday, June 27th. Maxim Group reaffirmed a “hold” rating on shares of Cellular Biomedicine Group in a research report on Friday, June 15th. BidaskClub lowered Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th. B. Riley set a $32.00 target price on Cellular Biomedicine Group and gave the stock a “buy” rating in a research report on Monday, May 21st. Finally, ValuEngine raised Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $25.00.
Cellular Biomedicine Group traded down $0.15, hitting $18.85, during trading hours on Wednesday, according to MarketBeat.com. The company had a trading volume of 14,946 shares, compared to its average volume of 58,527. Cellular Biomedicine Group has a fifty-two week low of $8.30 and a fifty-two week high of $22.75. The firm has a market capitalization of $332.28 million, a PE ratio of -10.59 and a beta of 3.40.
Cellular Biomedicine Group (NASDAQ:CBMG) last released its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.05). Cellular Biomedicine Group had a negative return on equity of 45.67% and a negative net margin of 9,594.83%. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.10 million. equities research analysts predict that Cellular Biomedicine Group will post -1.72 earnings per share for the current year.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.